tracking

Healthcare’s Once-in-a-Generation Disruption

The cost of healthcare in the United States continues to rise and the availability continues to decline. Healthcare spending accounts for 18% of U.S. GDP, and the costs in the U.S. are the highest in the world, increasing 130% in just the last decade. With this complexity comes an opportunity for entrepreneurs, innovators, and investors. iSelect is focused on finding technologies and innovations that reduce costs, increase accessibility, and improve quality of care.

Our Companies | Our Network | Join Our Network | News

iSelect Portfolio Companies

iSelect focuses on early-stage healthcare companies that are poised to help push the next healthcare revolution forward. We deliberately invest in companies that can make a positive impact on our society, as well as on the bottom line.

GeneMatters is a SaaS and telehealth platform that makes the genetic counseling process 4-5 times more efficient than it is today. Genetic testing is exploding with almost 70,000 genetic tests available today, and approximately 10 new tests added daily. Genetic counselors are in short supply and high demand.
Learn more…

Cofactor Genomics uses proprietary RNA sequencing technology and machine learning algorithms to diagnose disease. RNA serves as a real-time barometer of a person’s health, as opposed to DNA which remains little changed throughout a person’s life and whose analysis is estimated to diagnose less than 5% of diseases. Compared to current methods, Cofactor’s patent pending RNA isolation technology allows the Company to detect specific RNA molecules from low-quality tissue samples, making 100x more patient specimens available for analysis.
Learn more…

Entac Medical is developing noninvasive devices for predictive and diagnostic medicine based on a novel, patented, platform technology, Previs Audio Spectral Analysis Technology (PASAT). The first application, PrevisEA, is a noninvasive, disposable, self-contained device that is clinically proven to predict postoperative ileus (POI) in surgical patients.
Learn more…

Neuros Medical, Inc., a Cleveland, Ohio based neuromodulation company, is focused on developing proprietary therapies for unmet needs to patients worldwide. The company’s patented platform technology, Altius® Electrical Nerve Block, is focused on elimination of chronic pain in a variety of applications including neuroma/residual limb pain, chronic post-surgical pain, and chronic migraine.
Learn more…

Indalo Therapeutics (formerly known as Antegrin Therapeutics, Inc.), based in St. Louis, MO is a biopharmaceutical company developing and testing novel compounds that inhibit the development of pulmonary (lung) fibrosis and other fibrotic diseases by inhibiting proteins that are the key drivers of the fibrotic process. Uncontrolled, fibrosis can cause diseased organs to stop functioning.
Learn more…

Gila is developing a treatment for obesity using naturally occurring hormones (PYY) known to induce satiety, leading to weight loss. Gila is developing formulations to be applied to the tongue prior to meals, which have successfully induced satiety in animal testing without causing the nausea like symptoms associated with injectable and other formulations.
Learn more…

Euclises Pharmaceuticals is developing and testing novel cyclooxygenase-2 (COX-2, an enzyme responsible for inflammation and pain) inhibitors designed to increase the anti-cancer potency and effectiveness of chemotherapy safely, offering new treatment options for patients suffering from colorectal, non-small cell lung and pancreatic cancers.
Learn more…

Immunophotonics, Inc., based in St. Louis, MO, is an early stage biotechnology company engaged in the development of a proprietary drug product for use in a minimally invasive therapeutic cancer vaccine (inCVAX) for the treatment of metastatic tumors. The approach is intended to trigger the body’s own anti-tumor immune response against cancerous cells. For more information, see http://www.immunophotonics.com.
Learn more…

Tansna Therapeutics, Inc., based in St. Louis, MO, is developing and testing anticonvulsant drugs for the treatment of epilepsy. Worldwide, at least 50 million people suffer from epilepsy, 30% of whom are unable to achieve adequate seizure control using existing medications. Tansna’s proprietary anticonvulsant compounds have been shown in animal testing to prevent seizures in such otherwise therapy-resistant patients.
Learn more…

Meet Our Selection Committee

Our Healthcare Selection Committee consists of industry and subject matter experts who help guide iSelect’s investment decisions. With firsthand experience and a true pulse on the industry, we consider these individuals key to our success in finding and investing in healthcare innovation.

Dr. John Talley, Chief Science Officer for Euclises Pharmaceuticals and SARmont,  brings over thirty years experience and a record as one of the world’s most successful medicinal chemists. He is best known as the co-inventor of the blockbuster COX-2 in …

Read full bio >

Bobby Sandage

Bobby Sandage is currently President and CEO of Euclises, Chairman of the Board of Immunophotonics, member of the board of directors of EDIS, and a member of the Cultivation Capital life sciences fund investment committee. He was formerly President and …

Read full bio >

Lila Solnica-Krezel is professor and head of Developmental Biology at Washington University St. Louis, School of Medicine.  She is currently investigating the cellular and molecular genetic mechanisms underlying vertebrate gastrulation, which has pract …

Read full bio >

Gian Cavallini oversees the development and execution of Advanced ICU Care’s medical staffing growth strategy and leads the implementation of various initiatives to position the company for continued growth. His expertise in development and operations, …

Read full bio >

Dr. Paul D. Olivo, M.D., Ph.D., has been the Chief Scientific Officer of Apath, LLC since 2000 and served as its President. Dr. Olivo is an Entrepreneur-in-Residence at BioGenerator, where he previously served as a Senior Entrepreneur-in-Residence. He …

Read full bio >

Don Imholz

Mr. Don Imholz is a business executive/leader with diverse experience in Operations and IT, extensive Board involvement, and a strong track record of creating sustainable competitive advantage. His expertise in cybersecurity, big data, digital transfor …

Read full bio >

Melissa Walker

A regulatory professional with over 27 years of experience in the medical products industry, Melissa currently serves as Founder, President and CTO at Graematter, Inc. and Senior VP Regulatory at Topera. Specialties include regulatory intelligence rese …

Read full bio >

Michael Beat

Presently leading Arch Cancer Care as Medical Director, Dr. Beat is a local expert in collaborative prostate cancer management. At a national level, he contributes to physician leadership committees within the US Oncology Network. Having earned an exec …

Read full bio >

Mr. Beuttenmuller possesses over 30 years experience in Corporate Finance with Emerson Electric, Esse Health, Essence Healthcare and Innovare. He is experienced in financial analysis, risk management, mergers and acquisitions, new business development, …

Read full bio >

Professor of Internal Medicine – Hematology, Oncology and Blood and Marrow Transplantation at UUniversity of Iowa Roy J. and Lucille A. Carver College of Medicine and former Professor of Medicine and Genetics at Washington University School of Medicine …

Read full bio >

Bryce Rutter

Dr. Rutter is founder and CEO of Metaphase Design Group, a design firm serving industrial, commercial and consumer product and packaging clients internationally.  He is an acknowledged specialist in ergonomic product design and a leading worldwide expe …

Read full bio >

Michael Nichols

Michael Nichols, Ph.D. presently serves as an investor and C level management for various startups. He serves as an Analyst for Vinlogx, a platform that acquires, stores, and analyses internal vehicle information enabling solutions across multiple auto …

Read full bio >

Chas Eggert

Charles R. (Chas) Eggert has 40 years of experience in the specialty chemicals industry with a proven track record of creating value for startups and large global businesses. Chas is an operating partner focused on specialty chemical investments with A …

Read full bio >

David Christenson

David Christenson joined BioGenerator as an Entrepreneur-in-Residence in 2015 focusing primarily on healthcare and specifically in information technology, care delivery and payment, and services. Over a 30-year career, David has developed substantive b …

Read full bio >

Renaldo Cataldo

An accomplished senior executive with start-ups, growth, and turn-around organizations, Renato developed a healthcare technology corporation, HealthTech Solutions, from a small start-up of 3 people to a national provider of technical solutions to healt …

Read full bio >

Join Our Healthcare Innovation Network

Join the thousands of entrepreneurs, investors, and industry professionals driving the future of healthcare.

Resources and News

Dehydration Nation: Preventing One of the Most Common Health Risks in Real-Time

Dehydration Nation: Preventing One of the Most Common Health Risks in Real-Time

Up to three-fourths of Americans are chronically dehydrated, and the condition can be far more debilitating than it might seem. Mild dehydration — literally, not drinking enough water on a day-to-day basis — can impair cognitive performance by up to 20%, affecting reaction time, mental accuracy and memory. More severe cases, however, can result can result in seizures, brain damage, shock, and death.

read more
RNA Is Becoming the New DNA, Opening New Doors in Medicine

RNA Is Becoming the New DNA, Opening New Doors in Medicine

If a person’s DNA is the roadmap of their lifetime health, their RNA is more of a real-time barometer, recording what happens in their body on a minute-by-minute basis. Our DNA stores and transfers genetic information, but remains little changed throughout our lives. At best, it can tell us about the probability we will someday develop various diseases — whether or not we will get cancer, for instance, or be susceptible to diabetes or heart disease — but it  can’t tell us much about our current health.

read more